Alpha 2.0
Login Register
» Authors » Michael M Shi

Michael M Shi

Explore the profile of Michael M Shi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 747
Followers 0
Related Specialties
Oncology
Pharmacology
Genetics
Top 10 Co-Authors
Stefan Kammerer
Andreas Braun
Matthew R Nelson
Xin Li
Jing Sun
Weiguo Su
Hu Zhou
Charles R Cantor
Hongyan Yin
Matthew Squires
Published In
Clin Cancer Res
Lancet Haematol
Am J Pharmacogenomics
Genome Res
Lancet Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 study
Zhao X, Sun J, Zhang Z, Chen M, Gong T, He G, et al.
Lancet Haematol . 2025 Jan; 12(2):e97-e108. PMID: 39799953
Background: Spleen tyrosine kinase inhibitors are potential treatment options for warm autoimmune haemolytic anaemia. This study aimed to assess the preliminary efficacy and safety of sovleplenib-an oral spleen tyrosine kinase...
2.
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study
Hu Y, Liu X, Zhou H, Wang S, Huang R, Wang Y, et al.
Lancet Haematol . 2024 Jun; 11(8):e567-e579. PMID: 38885672
Background: Sovleplenib, a novel spleen tyrosine kinase (SYK) inhibitor, showed promising safety and activity in patients with primary immune thrombocytopenia in a phase 1b/2 trial. We aimed to evaluate the...
3.
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy
Musolino A, Campone M, Neven P, Denduluri N, Barrios C, Cortes J, et al.
Breast Cancer Res . 2017 Feb; 19(1):18. PMID: 28183331
Background: Overexpression of fibroblast growth factor receptor 1 (FGFR1), found in ≤8% of hormone receptor-positive (HR), human epidermal growth factor receptor 2-negative (HER2) breast cancer cases, is correlated with decreased...
4.
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
Motzer R, Porta C, Vogelzang N, Sternberg C, Szczylik C, Zolnierek J, et al.
Lancet Oncol . 2014 Feb; 15(3):286-96. PMID: 24556040
Background: An unmet medical need exists for patients with metastatic renal cell carcinoma who have progressed on VEGF-targeted and mTOR-inhibitor therapies. Fibroblast growth factor (FGF) pathway activation has been proposed...
5.
Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells
Konecny G, Kolarova T, OBrien N, Winterhoff B, Yang G, Qi J, et al.
Mol Cancer Ther . 2013 Feb; 12(5):632-42. PMID: 23443805
The recent identification of activating fibroblast growth factor receptor 2 (FGFR2) mutations in endometrial cancer has generated an opportunity for a novel target-based therapy. Here, we explore the therapeutic potential...
6.
A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
Deng N, Goh L, Wang H, Das K, Tao J, Tan I, et al.
Gut . 2012 Feb; 61(5):673-84. PMID: 22315472
Objective: Gastric cancer is a major gastrointestinal malignancy for which targeted therapies are emerging as treatment options. This study sought to identify the most prevalent molecular targets in gastric cancer...
7.
Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma
Kim K, Chesney J, Robinson D, Gardner H, Shi M, Kirkwood J
Clin Cancer Res . 2011 Oct; 17(23):7451-61. PMID: 21976540
Purpose: Dovitinib (TKI258) is an orally available inhibitor of fibroblast growth factor (FGF), VEGF, and platelet-derived growth factor receptors. This phase I/II dose-escalation study was conducted to evaluate the safety,...
8.
Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy
Koukourakis M, Giatromanolaki A, Sivridis E, Gatter K, Trarbach T, Folprecht G, et al.
Clin Cancer Res . 2011 Jun; 17(14):4892-900. PMID: 21632858
Purpose: The Colorectal Oral Novel therapy For the Inhibition of angiogenesis and Retarding of Metastases (CONFIRM)-randomized trials, investigating the role of the VEGF-receptor inhibitor PTK787/ZK 222584 (vatalanib) in colorectal cancer...
9.
Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer
Hida T, Tamiya M, Nishio M, Yamamoto N, Hirashima T, Horai T, et al.
Cancer Sci . 2011 Jan; 102(4):845-51. PMID: 21205086
ASA404 (5,6-dimethylxanthenone-4-acetic acid, vadimezan), a flavone-8-acetic acid analogue, is a novel tumor-vascular disrupting agent. In this study, the safety and tolerability, pharmacokinetics and pharmacodynamics of ASA404 in combination with standard...
10.
BRAF polymorphisms and risk of melanocytic neoplasia
James M, Roth R, Shi M, Kammerer S, Nelson M, Stark M, et al.
J Invest Dermatol . 2005 Dec; 125(6):1252-8. PMID: 16354196
Somatic mutations of the BRAF gene are common in melanomas and nevi but the contribution of polymorphisms in this gene to melanoma or nevus susceptibility remains unclear. An Australian melanoma...